Healthcare products company West Pharmaceutical Services (NYSE:WST) will be reporting earnings this Thursday before market hours. Here’s what to look for. West Pharmaceutical Services beat analysts’ ...

Is WST a good stock to buy? We came across a bullish thesis on West Pharmaceutical Services, Inc. on MaxDividends’s Substack. In this article, we will summarize the bulls’ thesis on WST. West ...

Conestoga Capital Advisors, an asset management company, released its fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. In Q4 2025, Conestoga Capital Advisors Mid Cap ...

Intraday Data provided by FACTSET and subject to terms of use. Historical and current end-of-day data provided by FACTSET. All quotes are in local exchange time. Real-time last sale data for U.S.

My estimations suggest that the U.S. government's cuts to its healthcare system will not have a significant negative impact on West Pharmaceutical's revenues. In Q2 2025, the company's revenues ...

West Pharmaceutical Services is headquartered in Exton, PA. The company's primary focus is developing, making and distributing containment and delivery systems for injectable drugs and healthcare ...

Sun, February 15, 2026 at 5:09 PM UTC West Pharmaceutical Services just sent investors $0.22 per share on February 4, 2026, marking the company's latest quarterly dividend payment. For a business that ...

Baron Funds, an investment management company, released its “Baron Asset Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. After a strong start to 2025, U.S.

Dividend Aristocrats like Atmos Energy, Colgate-Palmolive and West Pharmaceutical Services offer steady income as geopolitical tensions and oil price spikes rattle markets.

Shares of West Pharmaceutical Services Inc. WST slid 3.01% to $231.09 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 1.52% ...

West Pharmaceutical Services, a global provider of solutions for drugs, biologics, gene therapies, and consumer healthcare products, recently announced its Q4 results, surpassing analysts’ ...